{"doi":"10.4049/jimmunol.5.2.145","title":"Experimental Study of the Sensitized Cholera Antigen","abstract":"<jats:title>Abstract</jats:title>\n               <jats:p>Knowing that ordinary heated vaccine has no complete prophylactic action upon experimental typhoid fever, Besredka (1), in 1902, first used the so-called sensitized vaccine, which was made by combining the living typhoid bacilli with the useful constituents of immune serum. Later he investigated with Metchnikoff (2) its prophylactic value against experimental typhoid fever, and they found it effective and not dangerous to the human body. In 1914 Ichikawa, in Japan, experimented with the non-heated sero-vaccine upon typhoid fever patients with good results. In 1916, when the outbreak of cholera was at its height in Japan, the cholera sensitized vaccine was prepared by Shiga and his associates (3) and favorable results were obtained. Later Yabe published an article on cholera vaccine, its weak reaction and rapid development of antibodies, as compared with the ordinary vaccine.</jats:p>\n               <jats:p>We regret, however, that the sensitized vaccine in solution is not stable, and thus it cannot be kept for a long time in soluble form. In order to keep the sensitized vaccine without losing its power, as long as possible, it has been made in powder form by drying it in a vacuum desiccator over calcium chloride. We found that the sensitized cholera vaccine powder thus prepared has nearly the same effect as the bacilli suspension in liquid form, even after a period of nineteen months. We shall describe the experimental results in the following manner:</jats:p>","journal":"The Journal of Immunology","year":1920,"id":606143,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1555888,"name":"Y Miura","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Experimental Study of the Sensitized Cholera Antigen","abstract":"<jats:title>Abstract</jats:title>\n               <jats:p>Knowing that ordinary heated vaccine has no complete prophylactic action upon experimental typhoid fever, Besredka (1), in 1902, first used the so-called sensitized vaccine, which was made by combining the living typhoid bacilli with the useful constituents of immune serum. Later he investigated with Metchnikoff (2) its prophylactic value against experimental typhoid fever, and they found it effective and not dangerous to the human body. In 1914 Ichikawa, in Japan, experimented with the non-heated sero-vaccine upon typhoid fever patients with good results. In 1916, when the outbreak of cholera was at its height in Japan, the cholera sensitized vaccine was prepared by Shiga and his associates (3) and favorable results were obtained. Later Yabe published an article on cholera vaccine, its weak reaction and rapid development of antibodies, as compared with the ordinary vaccine.</jats:p>\n               <jats:p>We regret, however, that the sensitized vaccine in solution is not stable, and thus it cannot be kept for a long time in soluble form. In order to keep the sensitized vaccine without losing its power, as long as possible, it has been made in powder form by drying it in a vacuum desiccator over calcium chloride. We found that the sensitized cholera vaccine powder thus prepared has nearly the same effect as the bacilli suspension in liquid form, even after a period of nineteen months. We shall describe the experimental results in the following manner:</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W1629581916","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.1122449,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"https://academic.oup.com/pages/standard-publication-reuse-rights","oa_locations":[{"url":"https://academic.oup.com/jimmunol/article-pdf/5/2/145/62917677/ji0050020145.pdf","host_type":"publisher"},{"url":"https://doi.org/10.4049/jimmunol.5.2.145","host_type":"journal"}],"fields_of_study":["Escherichia coli research studies","Vibrio bacteria research studies","Salmonella and Campylobacter epidemiology"],"mesh_terms":[],"keywords":["Typhoid fever","Cholera","Typhoid vaccine","Cholera vaccine","Outbreak","Virology","Immunology","Medicine","Antigen","Immune system","Microbiology","Biology","Vibrio cholerae","Bacteria"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T03:58:28.897657Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}